S'abonner

Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: A prospective controlled trial - 02/09/11

Doi : 10.1067/mjd.2001.110645 
Uwe Wollina, MDa, Annette Looks, MDa, Jochen Meyer, MDb, Burkhard Knopf, MDc, Hans-Jürgen Koch, MDd, Kristin Liebold, MDa, Uta-Christina Hipler, Dr. rer. nat.a
From the Department of Dermatology, Friedrich-Schiller-University of Jena,a the Department of Dermatology, Waldklinikum Gera,b the Department of Dermatology, Heinrich-Braun-Klinikum Zwickau,c and the Department of Dermatology, DRK-Krankenhaus Chemnitz-Rabenstein. 

Abstract

Background: Both interferon alfa and extracorporeal photochemotherapy have been shown to be effective in primary cutaneous T-cell lymphomas (CTCLs). However, no prospective trial has been published on the combination of both treatments, although retrospective investigations suggested a better efficacy than for either interferon or extracorporeal photochemotherapy. Objective: Our purpose was to evaluate the efficacy and toxicity of combined interferon alfa-2a with extracorporeal photochemotherapy in a prospective controlled trial. Methods: A prospective controlled study was performed. Fourteen patients (all male) aged 38 to 72 years with CTCL of the mycosis fungoides type, stage IIa/IIb, and a 72-year-old male patient with a Ki-1 lymphoma were treated twice a month for 6 months with extracorporeal photochemotherapy using oral 8-methoxypsoralen as photosensitizer in combination with interferon alfa-2a subcutaneously 3 times a week in the maximal tolerable dosage (ie, up to 18 × 106 U). The effects were investigated by a skin score, staging, histologic score (density of the T-cell infiltrate; from 0 = absent to 3 = heavy), immunohistology, and laboratory investigations including total peripheral T-cell count, CD4/CD8 ratio, and soluble interleukin 2 receptor (sIL-2R). Results: After 6 months, best response was a complete response (CR) in 4 patients, a partial response (PR) in 3, and a stable disease (SD) in 7 of 14 patients (overall response rate [CR + PR] 50%). In responders the time to best response was 4.3 ± 1.4 months. The skin score decreased from 22.5 ± 8.1 to 15.1 ± 11.0 (P < .001), the histologic score decreased from 2.57 ± 0.51 to 1.21 ± 0.80 (P < .001). In the lesional skin the percentage of CD4 cells decreased from 75% to 51% (P = .038) and Ki-67-positive cells decreased from 6.7% to 2.4% (P = .001). The total T-cell count/μL decreased from 1018.9 ± 557.1 to 667.9 ± 417.9 (P = .012), and the CD4/CD8 ratio also decreased from 1.88 ± 0.92 to 1.51 ± 0.67 (P = .038). The sIL-2R levels did not change significantly during the first 4 months of treatment. Among patients of stage IIa the response rate was 60% in contrast to only 25% of those in stage IIb. Side effects were seen temporarily, ranging from grade 0 to grade 3. There was no need for additional therapy, but interferon dose was decreased because of side effects. After 1 year of follow-up the total response rate was 46.2% (6 of 13 patients): 5 of 9 with stage IIa(55.6%) and 1 of 4 with stage IIb (25.0%). Conclusion: These results indicate that patients with CTCL stage IIa can achieve a total response rate of 56% with combined interferon alfa-2a and extracorporeal photochemotherapy. Responders seem to experience their best response within the first 6 months of treatment. The treatment is well tolerated and does not cause severe side effects. (J Am Acad Dermatol 2001;44:253-60.)

Le texte complet de cet article est disponible en PDF.

 Supported by a grant from “Verbund Klinischer Forschung” (to U. W.) at the Medical School of the Friedrich-Schiller-University of Jena.


© 2001  The American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 44 - N° 2

P. 253-260 - février 2001 Retour au numéro
Article précédent Article précédent
  • The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata
  • Stefanie C. Behrens-Williams, Ulrike Leiter, Ralf Schiener, Michael Weidmann, Ralf U. Peter, Martina Kerscher
| Article suivant Article suivant
  • Utility of anti-bacillus Calmette-Guérin antibodies as a screen for organisms in sporotrichoid infections
  • Julie Byrd, Darius R. Mehregan, David A. Mehregan

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.